coronary artery calcium (CAC) score is a surrogate for atherosclerosis that strongly predicts incident coronary artery disease and major CVD events, independent of traditional risk factors. The prevalence of CAC deposition in SLE patients over the age of 45 is known to be significantly higher compared with the Multi-Ethnic Study of Atherosclerosis (MESA) cohort, however data on patients<45 years of age is scarce. evaluated CAC scores in younger SLE patients, compared with healthy controls from the Coronary Artery Risk Development in Young Adults (CARDIA) cohort.

Methods We identified 76 SLE patients meeting 1997 ACR classification criteria, without known coronary artery disease and who had a non-contrast CT chest performed as part of their clinical care, with images retrievable for calculation of CAC scores, using the Agatston score. Demographics, disease characteristics, and comorbidities were ascertained. Prevalence of any calcification, defined as CAC>0, was reported and compared with data from the CARDIA cohort, a large biracial U.S. cohort of patients ages 33 to 45 at time of chest CT scan for CAC determination. Additionally, within our SLE cohort, we investigated the relationship between disease characteristics and presence of any coronary artery calcification.

Results 76 SLE patients were studied (40±13 years old, 90% female, 33% Hispanic, 40% African American, disease duration 7±6 years). Patients met on average 6±2 ACR-SLE classification criteria; all had positive ANA titers, 64% had elevated dsDNA titers. Average SLE disease severity index1 was moderate at 5±3, 46% had lupus nephritis (LN) and 37% tested positive for antiphospholipid (APL) antibodies. The prevalence of CAC>0 was 42% for patients of all ages, 32% for age <45, 62% for age 45. CAC scores were between 1 and 100 in 72% of the patients and >100 for the remaining 28%. When compared with the CARDIA subjects, more SLE patients ages<45 had a CAC>0 (32.0% vs 9.6%, p-value<0.00001). Additionally, 29% of SLE patients age 18 to 32, with 5 years median SLE disease duration, had abnormal CAC scores; the youngest of whom was 21 years old. SLE patients with CAC were more likely to be older, have a history of a HTN, and have higher BMI. There were no significant differences in SLE disease duration, SLE severity index, APL antibodies, prevalence of LN, or smoking status, between patients with and without CAC.

Conclusions Young SLE patients have a significantly higher CAC scores compared with the general population. A CAC >0 was seen in 32% and 29% of SLE patients<45 and<33 years old, respectively. Our data suggest that subclinical atherosclerosis in SLE develops as early as the second decade of life, and warrant screening and cardio-protective interventions.

Funding Source(s): None

Background Antiphospholipid syndrome (APS) is characterized by spontaneous and recurrent vascular thromboembolic and thrombocytopenia. Cardiac manifestations are rare, but may occur in cardiac masses, such as thrombus (Libman-Sacks endocarditis). On the other hand, it is known that the most common type of primary cardiac tumors, myxoma, can produce clinical pictures similar to APS and SLE, and that tumor exeresis resolves symptoms.

Methods We examined 2 patients diagnosed with SLE and APS that presented cardiac mass. They were assessed with careful history taking, physical examination, laboratory tests, echocardiography and histological examination.

Results Case 1. A 13-years-old girl, with history of autoimmune hemolytic anemia treated with corticosteroids, folic acid and splenectomy a year before, presented a right ischemic stroke with hemiparesis sequel. Laboratory tests revealed ANA, antiDNA, aCL and lupus anticoagulant positive and echocardiography showed a cardiac mass. She was underwent surgery to exeresis the mass, which was compatible with myxoma. She was diagnosed with immune syndrome secondary to myxoma and did not take treatment. Seven months after the complete exeresis of the myxoma, she was admitted to our hospital because of two months fever, polyarthralgia, oral ulcers and malar rash. Echocardiography showed pericardial effusion and blood tests showed lymphopenia, anemia, ANA and antiDNA positive and elevation of acute phase reactants; urinalysis was normal. She was diagnosed with SLE flare and was successfully treated with corticoids and started hydroxychloroquine, azathioprine and acetylsalicylic acid.

The second case is a 48-years-old woman diagnosed with SLE and associated APS (oral ulcers, thrombosis, arthritis, malar rash, ANA, Coombs and aCL positive), with a history of bilateral iliac arterial ischemia caused by myxoma emboli (confirmed by histological examination) and a cardiac mass on echocardiogram. Fourteen months after the vascular surgery, the patient still needs treatment with rituximab, azathioprine and corticoids to control SLE activity and is on anticoagulant treatment to prevent thrombotic episodes.

Conclusions In patients with myxoma and symptoms of APS and/or SLE, there is doubt whether these are secondary to myxoma or if these diseases coexist, so it is recommended to closely monitor clinical activity after exeresis of myxoma and consider not suspending immunosuppressants and/or anticoagulants or the progressive withdrawal of drugs according to symptoms, in order to avoid possible serious complications of autoimmune disease.

Funding Source(s): None

Background Systemic lupus erythematosus (SLE) is an autoimmune disease that is more severe in pediatric population than...
in adults. Biological therapy with anti-CD20 (rituximab) is an option in patient that does not respond to conventional therapy.

**Methods** The aim of this study is to determine the clinical and immunological response in 10 patients with cSLE that received treatment with rituximab in a third level hospital. 10 patients treated with Rituximab between November 2007 and October 2018 was included in a retrospective observational study. The response to treatment at 6 months and one year after the first infusion of Rituximab were assessed. All patients fulfilled four or more of the 1982 revised American College of Rheumatology criteria for the diagnosis of SLE (<16 years).

**Results** Ten cSLE patients treated with rituximab were included, all of them were female. The age at diagnosis of SLE was a mean of 15.61 years. The mean time duration of disease was 87.55 months (5255 m). 8 patients were caucasians. Rituximab was indicated in 60% of patients for class IV of lupus nephritis (LN), in 10% for class III LN, 10% for Class II LN, 10% for severe cutaneous lupus, and for severe hematological manifestations in 10% of cases (haemolytic anemia). In addition, 60% of the patients had mucocutaneous and articular manifestations. The disease activity of all patients was assessed using SELENA-SLEDAD (Suppl 1):A1–A227

**Background** Complement plays a central role in SLE. Its activation by immune complexes drives type II and III hypersensitivity reactions and classical pathway activation, leading to inflammatory responses in target tissues. Its activation generates an array of bioactive soluble and cell-bound complement activation products (CB-CAPs). Data are lacking detailing the types and quantities of each CB-CAP on SLE immune cells. We speculate that discerning the patterns and impacts of complement signatures on SLE B cells will provide insight into the role of complement activation in the pathogenesis of SLE. To characterize the array of CB-CAPs on SLE immune cells, we created and validated a mass cytometry (MC) panel suitable for detecting over 20 CB-CAPs and complement receptors, then examined PBMCs from paired flare and inactive samples from patients with SLE.

**Methods** Adults with ACR- or SLICC-classified SLE (n=5) were enrolled and consented for PBMC collection at Washington University School of Medicine. Paired samples were obtained, one during a flare and one after resolution of the flare. Frozen ficoll gradient isolated buffy coat PBMCs were thawed counted, filtered, and treated with cisplatin to confirm viability. Prepared cells were stained with metal-conjugated antibodies to measure surface complement proteins and markers identifying immune cell subset. Stained cells were treated with an Iridium intercalator, recounted, washed in Milli-Q water to remove salts, resuspended with a solution of bead standards to facilitate data normalization, and subjected to single cell MC. Sample to sample consistency is optimized by simultaneously examining multiple cell preparations barcoded with palladium metals. Data analysis was performed with Cytobank. Distinct cell sub-populations were identified and organized in a hierarchal fashion.

**Results** We found the highest frequency of C4d deposition (indicative of classical pathway activation) on B cells compared to T cells and monocytes during SLE flares. Surprisingly, only B cells had C3d, C5 (common pathway), and Bb (alternative pathway) CAPs with none observed on T cells or monocytes suggesting that incomplete classical pathway activation occurred on these cells. We also found that different B cell subsets differentially activated complement During flares. Transitional B cells universally had C4d and C5 but surprisingly had little C3d, despite the presence of Bb. Mature B cells, particularly the mature anergic subset, and memory B cells had C4d and C3d but little C5. Plasma cells/plasmablasts were devoid of any CB-CAPs. Finally, during disease inactivity, very low levels of all CB-CAPs were observed on all PBMCs.

**Conclusions** We found a high level of CB-CAP deposition in immune cells obtained from subjects with a SLE flare, which was absent during disease inactivity. The types of CB-CAPs on PBMCs were not uniform, and our data suggest that certain immune cells appear regulate complement activation while others do not. The reasons for this are unclear, but it potentially opens up a previously undescribed heterogeneity in SLE. These pilot data demonstrate the feasibility of the MC complement panel on human samples and the power of this approach in discovering novel mechanisms of complement activation and regulation.

**Funding Source(s):** AHK: NIH/NIAMS R21 AR069833, Doris Duke Charitable Foundation